DK2589592T3 - Hidtil ukendte nicotinamidderivater eller salte deraf - Google Patents

Hidtil ukendte nicotinamidderivater eller salte deraf Download PDF

Info

Publication number
DK2589592T3
DK2589592T3 DK11801034.7T DK11801034T DK2589592T3 DK 2589592 T3 DK2589592 T3 DK 2589592T3 DK 11801034 T DK11801034 T DK 11801034T DK 2589592 T3 DK2589592 T3 DK 2589592T3
Authority
DK
Denmark
Prior art keywords
group
amino
cis
nicotinamide
fluoro
Prior art date
Application number
DK11801034.7T
Other languages
English (en)
Inventor
Hideyasu Fujiwara
Kimihiko Sato
Shinsuke Mizumoto
Yuichiro Sato
Hideki Kurihara
Yohei Kubo
Hiyoku Nakata
Yasutaka Baba
Takashi Tamura
Hidenobu Kuniyoshi
Shinji Hagiwara
Mari Yamamoto
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Application granted granted Critical
Publication of DK2589592T3 publication Critical patent/DK2589592T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)

Claims (28)

  1. HIDTIL UKENDTE NICOTINAMIDDERIVATER ELLER SALTE DERAF E Nicotinamidderivat, der er repræsenteret ved følgende formel (I) eller et salt deraf:
    hvor R1 repræsenterer et halogenatom; R2 er en substituent, der er repræsenteret ved en hvilken som helst af følgende formler (II) til (V) og (VII):
    hvor R10, R11, R12, R13, R16, R17, R18, R20 og R21 hver uafhængigt repræsenterer et hydrogenatom, eller en ( )-<,-alkyl-. C2.6-alkenyl-, C2.6-alkynyl-, C3.8-cycloalkyl-, aryl-, C μ,,-alkoxy-, aryloxy-, acyl-, Ομ6-alkylsulfonyl-, arylsulfonyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent, R14, R15, R19 og R30 hver uafhængigt repræsenterer et hydrogenatom, eller en ( 'μμ-alkyl- eller acylgruppe, der hver eventuelt har mindst én substituent, Xs repræsenterer et oxygenatom, et svovlatom eller =NR23 (hvor R23 repræsenterer et hydrogenatom, eller en Ομι2-8^γ1-, C2.12-alkenyl-, C2.12-alkynyl-, C3.8-cycloalkyl- eller Co6-alkoxygruppe, der hver eventuelt har mindst én substituent), R22 repræsenterer en heterocyklisk gruppe med eventuelt mindst én substituent, X9 og X10 hver uafhængigt repræsenterer et oxygenatom, -NR31- (hvor R31 repræsenterer et hydrogenatom, eller en ( 'μμ-alkyl-. C2.12-alkenyl-, C2.12-alkynyl-, C3.8-cycloalkyl-, Ομ 6-alkoxy-, acyl-, ( ’μ,,-alkoxycarbonyl-, aryloxycarbonyl- eller heterocyklisk oxycarbonylgruppe, der hver eventuelt har mindst én substituent), eller en methylengruppe (hvor en af X9 og X10 repræsenterer en methylengruppe, og, når m3 er 0, X10 repræsenterer en methylengruppe), ml og m3 hver uafhængigt repræsenterer et heltal fra 0 til 2, m2 repræsenterer et heltal på 1 eller 2, hvor R20 og R21 kan være forskellige, når m2 er 2, n repræsenterer et heltal fra 0 til 4, R16 kan være forskellige, når n er 2 tiil 4, og hvor R10 og R11, R12 og R13, R17 og R18 og R20 og R21 sammen kan danne en C3.8-cycloalkyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent; R3 repræsenterer en arylgruppe eventuelt med mindst én substituent eller en heterocyklisk gruppe med eventuelt mindst én substituent; og
    R4 og R5 hver uafhængigt repræsenterer et hydrogenatom, en Q.^-alkylgruppe, en C2.12-alkenylgruppe eller en C2.12-alkynylgruppe; hvor arylgruppen er en phenyl-, naphthyl-, indanyl- eller indenylgruppe; hvor den heterocykliske gruppe er valgt fra azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, piperidyl, tetrahydropyridyl, pyridyl, homopiperidinyl, octahydroazocinyl, imidazolidinyl, imidazolinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, homopiperazinyl, triazolyl, tetrazolyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, morpholinyl, thiazolyl, isothiazolyl, thiadiazolyl, thiomorpholinyl, 1-oxide-thiomorpholinyl, 1,1-dioxide-thiomorpholinyl, indolinyl, indolyl, isoindolinyl, isoindolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, tetrahydroquinolinyl, quinolyl, tetrahydroisoquinolinyl, isoquinolinyl, quinolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, dihydroquinoxalinyl, quinoxalinyl, naphthyridinyl, pyrrolopyridyl, imidazopyridyl, indolidinyl, dihydrocyclopentapyridyl, triazolopyridyl, pyrazolopyridyl, pyridopyrazyl, purinyl, pteridinyl, quinuclidinyl, 2,3-dihydrobenzofuranyl, benzofuranyl, isobenzofuranyl, chromanyl, chromenyl, isochromanyl, 1,3-benzodioxolyl, 1,3-benzodioxanyl, 1,4-benzodioxanyl, 2,3-dihydrobenzothienyl, benzothienyl, benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzomorpholinyl, dihydropyranopyridyl, dihydrodioxinopyridyl, 1,3-dioxolopyridyl, dihydropyridooxazinyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl og thiazolopyridyl; hvor substituenten eventuelt med substituenter repræsenteret ved R2 er valgt fra substituentgruppen «1-2, hvor substituentgruppen αμ2 består af et halogenatom; en cyangruppe; en nitrogruppe; en oxogruppe; en eventuelt beskyttet carboxylgruppe; en eventuelt beskyttet hydroxylgruppe; en eventuelt beskyttet aminogruppe; en C|.,,-alkylgriippe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en C2.6-alkenylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe βι-ι; en C2-6-alkynylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en C3.8-cycloalkylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en arylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe βι-ι; en Ci_6-alkoxygruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en aryloxygruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en acylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en ()-,4alkylsull'onylgruppc eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en arylsulfonylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β14; en heterocyklisk gruppe med eventuelt mindst én substituent, der er valgt fra følgende substituentgruppe β14; og en gruppe, der er repræsenteret ved formlen -Q1-Q2-NR6R7 (hvor R6 og R7 hver uafhængigt repræsenterer et hydrogenatom, en aminobeskyttelsesgruppe, en Ci_6-alkylgruppe eventuelt med mindst én substituent, en C2.6-alkenylgruppe eventuelt med mindst én substituent, en C2.6-alkynylgruppe eventuelt med mindst én substituent, en C3.8-cycloalkylgruppe eventuelt med mindst én substituent, en Ci_6-alkoxygruppe eventuelt med mindst én substituent, en arylgruppe eventuelt med mindst én substituent, eller en heterocyklisk gruppe med eventuelt mindst én substituent, eller R6 og R7 kan danne en cyklisk aminogruppe eventuelt med mindst én substituent, sammen med det nitrogenatom, hvortil de binder; Q1 repræsenterer -NH-, en C μ,,-alkylengruppe eventuelt med mindst én substituent, en C2.6- alkenylengruppe eventuelt med mindst én substituent, en C2.6-alkynylengruppe eventuelt med mindst én substituent, eller en binding; Q2 repræsenterer en gruppe, der er repræsenteret ved-C(=X7)- (hvor X7 repræsenterer et oxygenatom, et svovlatom, eller en gruppe, der er repræsenteret ved =NR29 (hvor R29 repræsenterer et hydrogenatom, en Q.^-alkylgruppe eventuelt med mindst én substituent, en C2.12-alkenylgruppe eventuelt med mindst én substituent, en C2_i2-alkynylgruppe eventuelt med mindst én substituent, en C3.8-cycloalkylgruppe eventuelt med mindst én substituent eller en C|.,,-alkoxygruppc eventuelt med mindst én substituent)), en C|.,,-alkylcngrappc. eller en binding), hvor substituentgruppen βμ består af et halogenatom, en cyangruppe, en nitrogruppe, en oxogruppe, en eventuelt beskyttet carboxylgruppe, en eventuelt beskyttet hydroxylgruppe, en eventuelt beskyttet aminogruppe, en C|.,,-alkylgi'iippc eventuelt med mindst ét halogenatom, en C3.8-cycloalkylgruppe eventuelt med mindst ét halogenatom, en C|.,,-alkoxygiTippc eventuelt med mindst ét halogenatom, en arylgruppe eventuelt med mindst ét halogenatom og en heterocyklisk gruppe med eventuelt mindst ét halogenatom; hvor substituenten, der eventuelt er i arylgruppen eller den heterocykliske gruppe, der er repræsenteret ved R3, er valgt fra følgende substituentgruppe a2.2, hvor substituentgruppen a2.2 består af et halogenatom; en cyangruppe; en nitrogruppe; en oxogruppe; en eventuelt beskyttet carboxylgruppe; en eventuelt beskyttet hydroxylgruppe; en eventuelt beskyttet aminogruppe; en C|.,,-alkylgrappc eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en C2.6-alkenylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en C2.6-alkynylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en C3.8-cycloalkylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.μ en arylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en C|.,,-alkoxygiTippc eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en aryloxygruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en acylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en ()-,,-alkylsiilfonylgiTippc eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en arylsulfonylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ en heterocyklisk gruppe med eventuelt mindst én substituent, der er valgt fra følgende substituentgruppe β2.ρ og en gruppe, der er repræsenteret ved formlen -Q3-Q4-NR24R25 (hvor R24 og R25 hver uafhængigt repræsenterer et hydrogenatom, en aminobeskyttelsesgruppe, en Ci_6-alkylgruppe eventuelt med mindst én substituent, en C2.6-alkenylgruppe eventuelt med mindst én substituent, en C2_6-alkynylgruppe eventuelt med mindst én substituent, en C3.8-cycloalkylgruppe eventuelt med mindst én substituent, en C|.f,-alkoxygiTippc eventuelt med mindst én substituent, en ar-Ci_6-alkylgruppe eventuelt med mindst én substituent, en arylgruppe eventuelt med mindst én substituent, en heterocyklisk gruppe med eventuelt mindst én substituent, eller R24 og R25 kan danne en cyklisk aminogruppe eventuelt med mindst én substituent, sammen med det nitrogenatom, hvortil de binder; Q3 repræsenterer -NH-, en C^-alkylengruppe eventuelt med mindst én substituent, en C2.6-alkenylengruppe eventuelt med mindst én substituent, en C2.6-alkynylengruppe eventuelt med mindst én substituent, eller en binding; og Q4 repræsenterer -C(=O)-, en Ci_6-alkylengruppe eller en binding); og hvor substituentgruppen β2_ består af et halogenatom, en cyangruppe, en nitrogruppe, en oxogruppe, en eventuelt beskyttet carboxylgruppe, en eventuelt beskyttet hydroxylgruppe, en eventuelt beskyttet aminogruppe, en C i ^-alkylgruppe eventuelt med mindst ét halogenatom, en C3.8-cycloalkylgruppe eventuelt med mindst ét halogenatom, en C i-,,-alkoxygruppc eventuelt med mindst ét halogenatom, en ar-C i -6-alkylgruppe eventuelt med mindst ét halogenatom, en arylgruppe eventuelt med mindst ét halogenatom, og en heterocyklisk gruppe med eventuelt mindst ét halogenatom.
  2. 2. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor substituenten eventuelt med substituenter repræsenteret ved R2 er valgt fra følgende substituentgruppe αμ3, hvor substituentgruppen αμ3 består af en cyangruppe; en oxogruppe; en eventuelt beskyttet hydroxylgruppe; en eventuelt beskyttet aminogruppe; en arylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe βμ2; en Cμ6-alkoxygruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe βμ2; en heterocyklisk gruppe med eventuelt mindst én substituent, der er valgt fra følgende substituentgruppe βμ2; og en gruppe, der er repræsenteret ved formlen -Q -Q -NR R (hvor Q , Q , R og R hver har de samme definitioner som de, der er beskrevet i krav 1); hvor substituentgruppen βμ2 består af et halogenatom og en eventuelt beskyttet aminogruppe.
  3. 3. Nicotinamidderivat eller et salt deraf ifølge et hvilket som helst af krav 1 eller krav 2, hvor R2 repræsenterer en Cμ12-alkylgruppe med, som en substituent, en eventuelt beskyttet aminogruppe eller en heterocyklisk gruppe med eventuelt mindst én substituent, eller en C3.8-cycloalkylgruppe med, som en substituent, en eventuelt beskyttet aminogruppe eller en heterocyklisk gruppe med eventuelt mindst én substituent.
  4. 4. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor R2 er en substituent, der er repræsenteret ved følgende formel (II-1):
    hvor R32 og R33 hver uafhængigt repræsenterer et hydrogenatom, eller en Cbe-alkyl-, C2_6-alkenyl-, C2.6-alkynyl-, C3.8-cycloalkyl-, aryl-, Ομ6-3Βκ>χγ-, aryloxy-, acyl-, Ομ6-3Βιγΐ8π1ίοηγ1-, arylsulfonyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent, der er valgt fra følgende substituentgruppe γμ2, hvor substituentgruppen γμ2 består af et halogenatom, og Ομ6-8^1-, C3.8-cycloalkyl-, aryl- og heterocykliske grupper, der hver eventuelt har mindst én substituent.
  5. 5. Nicotinamidderivat eller et salt deraf ifølge krav 4, hvor R32 repræsenterer en-alkylgruppe; en alkylgruppe, der er substitueret med en cycloalkylgruppe; en cycloalkylgruppe; eller en cycloalkylgruppe, der er substitueret med en alkylgruppe, der hver i alt indeholder 3 til 5 carbonatomer, eller en alkoxyalkylgruppe, der i alt indeholder 2 til 4 carbonatomer.
  6. 6. Nicotinamidderivat eller et salt deraf ifølge krav 4, hvor R32 repræsenterer en methyl- eller ethylgruppe, der er substitueret med en heterocyklisk gruppe.
  7. 7. Nicotinamidderivat eller et salt deraf ifølge et hvilket som helst af kravene 4 til 6, hvor R33 repræsenterer et hydrogenatom, eller en C i .,,-alkyl- eller C3.8-cycloalkylgruppe.
  8. 8. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor R2 er en substituent, der er repræsenteret ved følgende (III-4):
  9. 9. Nicotinamidderivat eller et salt deraf ifølge et hvilket som helst foregående krav, hvor R4 og R5 hver repræsenterer et hydrogenatom.
  10. 10. Nicotinamidderivat eller et salt deraf ifølge krav 1, der er repræsenteret ved følgende formel (I-1):
    hvor R26 er en substituent, der er repræsenteret ved en hvilken som helst af ovenstående formler (II) til (V) og (VII), og R3 er som defineret i krav 1.
  11. 11. Nicotinamidderivat eller et salt deraf ifølge et hvilket som helst foregående krav, hvor arylgruppen eller den heterocykliske gruppe, der hver eventuelt har mindst én substituent, repræsenteret ved R3, er en phenyl-, pyridyl-, pyridazinyl-, quinoxalinyl- eller indazolylgruppe.
  12. 12. Nicotinamidderivat eller et salt deraf ifølge krav 11, hvor arylgruppen eller den heterocykliske gruppe, der hver eventuelt har mindst én substituent, der er repræsenteret ved R3, er en pyridyl-, quinoxalinyl- eller indazolylgruppe.
  13. 13. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor substituenten eventuelt i arylgruppen eller den heterocyklisk gruppe, der er repræsenteret ved R3, er valgt fra følgende substituentgruppe a2.3, hvor substituentgruppen a2.3 består af et halogenatom; en cyangruppe; en nitrogruppe; en oxogruppe; en eventuelt beskyttet carboxylgruppe; en eventuelt beskyttet aminogruppe; en Q.g-alkylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en C3.8-cycloalkylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en arylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en C|.,,-alkoxygiTippc eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en aryloxygruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en acylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en C^-alkylsulfonylgruppe eventuelt med mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; en heterocyklisk gruppe med eventuelt mindst én substituent, der er valgt fra følgende substituentgruppe β2.2; og en gruppe, der er repræsenteret ved formlen -Q3-Q4-NR24R25 (hvor Q3, Q4, R24 og R25 er som defineret i krav 1); hvor
    substituentgruppen β2.2 består af et halogenatom, en eventuelt beskyttet hydroxylgruppe, en Ci_6-alkylgruppe eventuelt med mindst ét halogenatom, en C3.8-cycloalkylgruppe eventuelt med mindst ét halogenatom, en C^-alkoxygruppe eventuelt med mindst ét halogenatom, en arylgruppe eventuelt med mindst ét halogenatom, og en heterocyklisk gruppe med eventuelt mindst ét halogenatom.
  14. 14. Nicotinamidderivat eller et salt deraf ifølge et hvilket som helst foregående krav, hvor R3 repræsenterer en pyridylgruppe eventuelt med en substituent, der er valgt fra følgende substituentgruppe a2. 4, hvor substituentgruppen a2.4 består af et halogenatom; en cyangruppe; en nitrogruppe; en oxogruppe; en eventuelt beskyttet carboxylgruppe; en eventuelt beskyttet hydroxylgruppe; en eventuelt beskyttet aminogruppe; en C|-,,-alkyl-. C2.6-alkenyl-, C2.6-alkynyl-, C3.8-cycloalkyl-, aryl-, C|.(,-alkoxy-, aryloxy-, acyl-, Ci_6-alkylsulfonyl-, arylsulfonyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent, der er valgt fra følgende substituentgruppe β2.3; og formlen -Q3-Q4-NR24R25 (hvor Q3, Q4, R24 og R25 har de samme definitioner som de, der er beskrevet ovenfor); hvor substituentgruppen β2.3 består af et halogenatom; en cyangruppe; en nitrogruppe; en oxogruppe; en eventuelt beskyttet carboxylgruppe; en eventuelt beskyttet hydroxylgruppe; en eventuelt beskyttet aminogruppe; og en -alkyl-. C3.8-cycloalkyl-, -Q5m4-R36 (hvor Q5 repræsenterer en Ci_6-alkylenoxygruppe (hvor R36-siden er en alkylengruppe), R36 repræsenterer et hydrogenatom, eller en Ci_6-alkyl-, C3.8-cycloalkyl-, aryl- eller heterocyklisk gruppe, m4 repræsenterer et heltal fra 1 til 3, og Q5 kan være forskellige, når m4 er 2 eller 3), aryl- eller heterocyklisk gruppe, der hver eventuelt har mindst ét halogenatom.
  15. 15. Nicotinamidderivat eller et salt deraf ifølge krav 14, hvor R3 repræsenterer en pyridylgruppe, der er repræsenteret ved følgende formel (VIII-1) eller (VIII-2):
    hvor R37, R38, R39, R40, R41, R42, R43 og R44 hver uafhængigt repræsenterer et hydrogenatom, eller en substituent, der er valgt fra følgende substituentgruppe a2_6; hvor substituentgruppen a2_6 består af et halogenatom; og en ().,,-alkyl-. C3.8-cycloalkyl-, aryl-, Ci_6-alkoxy- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent, der er valgt fra følgende substituentgruppe β2.5; hvor substituentgruppen β2.5 består af et halogenatom; og en ( -alkyl-. C3.8-cycloalkyl-, -Q5m4-R36 (hvor Q5, R36, og m4 har de samme definitioner som de, der er beskrevet ovenfor), aryl- eller heterocyklisk gruppe, der hver eventuelt har mindst ét halogenatom.
  16. 16. Nicotinamidderivat eller et salt deraf ifølge krav 15, hvor R3 repræsenterer en pyridylgruppe, der er repræsenteret ved følgende formel (VIII-3) eller (VIII-4):
    hvor R45, R46, R47 og R48 hver uafhængigt repræsenterer et hydrogenatom, eller en substituent, der er valgt fra den ovenfor beskrevne substituentgruppe α2-6·
  17. 17. Nicotinamidderivat eller et salt deraf ifølge krav 16, hvor R45 repræsenterer en 5-leddet ring heterocyklisk gruppe eventuelt med mindst én substituent, der er valgt blandt et halogenatom, en Ci_6-alkyl-, C3.8-cycloalkyl- og -Q5m4-R36 (hvor Q5, R36, og m4 er som defineret i krav 15), og R48 repræsenterer et halogenatom, en C|.,,-alkylgruppc eller en C|.,,-alkoxygrppc.
  18. 18. Nicotinamidderivat eller et salt deraf ifølge krav 16, hvor R45 repræsenterer et halogenatom; eller en C|.,,-alkyl- eller C|.,,-alkoxygriippc eventuelt med mindst ét halogenatom, og R46 repræsenterer en 5-leddet ring eller 6-leddet ring heterocyklisk gruppe, der hver eventuelt har mindst én substituent, der er valgt blandt et halogenatom, Ci_6-alkyl, C3.8-cycloalkyl og -Q5m4-R36 (hvor Q5, R36 og m4 er som defineret i krav 15).
  19. 19. Nicotinamidderivat eller et salt deraf ifølge krav 16, hvor R47 og R48 hver uafhængigt repræsenterer et hydrogenatom; et halogenatom; eller en ( -alkyl-, aryl-, C,.,,-alkoxy- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent uafhængigt valgt blandt et halogenatom, Ci-6-alkyl, C3.8-cycloalkyl og -Q5m4-R36 (hvor Q5, R36 og m4 er som defineret i krav 15).
  20. 20. Nicotinamidderivat eller et salt deraf ifølge krav 14, hvor R3 repræsenterer en indazolylgruppe, der er repræsenteret ved en hvilken som helst af følgende formler (IX-1) til (IX-6):
    hvor R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77 og R78 hver uafhængigt repræsenterer et hydrogenatom, eller en substituent, der er valgt fra den ovenfor beskrevne substituentgruppe a2_6 som defineret i krav 15.
  21. 21. Nicotinamidderivat eller et salt deraf ifølge krav 20, hvor R3 repræsenterer en indazolylgruppe, der er repræsenteret ved følgende formel (IX-7) eller (IX-8):
    hvor R79, R80, R81 og R82 hver uafhængigt repræsenterer et hydrogenatom, eller en substituent, der er valgt fra den ovenfor beskrevne substituentgruppe «20 som defineret i krav 15.
  22. 22. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor formlen (I) er repræsenteret ved følgende formel (1-2):
    hvor R83, R84, R85 og R86 hver uafhængigt repræsenterer et hydrogenatom, eller en Ct_6-alkyl-, C2.6-alkenyl-, C2.6-alkynyl-, C3.8-cycloalkyl-, aryl-, ().,,-alkoxy-, aryloxy-, acyl-, ()-,,-alkylsulfonyl-. arylsulfonyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent, der er valgt fra substituentgruppen αμ2 som defineret i krav 1, R87 har de samme definitioner som de af R3 som defineret i krav 1, hvor R83 og R84, og R85 og R86 sammen kan danne en C3.8-cycloalkyl- eller heterocyklisk gruppe, der hver eventuelt har mindst én substituent.
  23. 23. Nicotinamidderivat eller et salt deraf ifølge krav 1, hvor formlen (I) er repræsenteret ved følgende formel (1-6):
    hvor R94 har de samme definitioner som de af R3 som defineret i krav 1.
  24. 24. Farmaceutisk sammensætning, der omfatter nicotinamidderivatet eller et salt deraf ifølge et hvilket som helst af kravene 1 til 23.
  25. 25. Farmaceutisk sammensætning ifølge krav 24, til anvendelse i behandling af reumatisme eller idiopatisk trombocytopenisk purpura.
  26. 26. Forbindelse, der er valgt fra gruppen bestående af: 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-phenylpyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(3-methylphenylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(4-(morpholin-4-yl)phenylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(3,4,5-trimethoxyphenylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methoxypyridin-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(2,6-dimethoxypyridin-4-ylamino)-5-fluornicotinamid;
    6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-(morpholin-4-yl)pyridin-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(6-(morpholin-4-yl)pyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(pyrimidin-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l,5-naphthyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l,6-naphthyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l,6-naphthyridin-8-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(8-nitroquinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-pyrrolo[2,3-c]pyridin-4- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-(pyrrolidin-l-yl)ethyl)-lH-pyrrolo[2,3-c]pyridin- 4- ylamino)nicotinamid; 2-(8-acetylaminoquinolin-3-ylamino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-(anilinocarbonyl)pyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-pyrrolo[2,3-b]pyridm-5- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-pyrrolo[2,3-b]pyridm-4- ylamino)nicotinamid; methyl-5-(3-aminoc arbon yl-6-(cis-2-aminocyclohexylamino)-5-fluorpyridin-2-ylamino)nicotinat; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(6-methylpyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methylpyridin-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-(pyrrolidin-l-yl)ethyl)-lH-pyrrolo[2,3-b]pyridin- 5- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-(pyrrolidin-l-yl)ethyl)-lH-pyrrolo[2,3-b]pyridin- 4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-(morpholin-4-yl)ethyl)-lH-pyrrolo[2,3-b]pyridin- 4- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-([l,3]thiazolo[4,5-b]pyTidin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l-(2-(diethylamino)ethyl)-lH-pyrrolo[2,3-b]pyridin-4- ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-methoxyethyl)-lH-pyrrolo[2,3-b]pyridin-4- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-isobutyl-lH-pyrrolo[2,3-b]pyridin-4- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l-cyclopropyl-lH-pyrrolo[2,3-b]pyridin-4-ylamino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l-(cyclopropylmethyl)-lH-pyrrolo[2,3-b]pyridin-4-ylamino)- 5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-(2H-l,2,3-triazol-2-yl)pyridin-3-ylamino)- nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-(lH-pyrrol-2-yl)pyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-(2-thienyl)pyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(5-cyclopropylpyridin-3-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-(2-furyl)pyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(8-aminoquinolin-3-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(lH-pyrrolo[2,3-b]pyridm-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(lH-pyrrolo[2,3-b]pyridm-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(lH-pyrrolo[2,3-c]pyridin-4-ylamino)nicotinamid; 2-(8-(aminocarbonyl)aminoquinolin-3-ylamino)-6-(cis-2-aminocyclohexylamino)-5- fluornicotinamid; 6-(2-aminoethylamino)-5-fluor-2-(pyridin-4-ylamino)nicotinamid; 6-(2-aminoethylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(2,1,3-benzothiadiazol-5-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l,3-benzothiazol-6-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-indazol-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methyl-l,3-benzoxazol-6-ylamino)nicotinamid; 6-(2-aminoethylamino)-2-(l,3-benzothiazol-6-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methyl-l,3-benzoxazol-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-methylpyridin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l,3-dimethyl-lH-pyrazolo[3,4-b]pyridin-5-ylamino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(2,3-dihydro-l,4-benzodioxin-6-ylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(3-(2H-l,2,3-triazol-2-yl)phenylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(6-methoxyquinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinolin-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinoxalin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(l,3-benzothiazol-5-ylamino)-5-fluornicotinamid; 6-(2-aminoethylamino)-5-fluor-2-(isoquinolin-4-ylamino)nicotinamid; 6-(2-aminoethylamino)-5-fluor-2-(quinolin-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-indazol-5-ylamino)nicotinamid; 6-(cis-2-aminocyc!ohexylamino)-5-fluor-2-(l-methyl-lH-benzoimidazol-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinazolin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinazolin-7-ylamino)nicotinamid; cis-6-(2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-benzoimidazol-5-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methylquinolin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinolin-7-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-methyl-lH-indazol-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-methylquinoxalin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l-(2-(pyrrolidin-l-yl)ethyl)-lH-indazol-5- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(2-(2-(pyrrolidin-l-yl)ethyl)-2H-indazol-5- ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-ftuor-2-(lH-indazol-5-ylamino)nicotinamid; 6-(2-aminoethylamino)-2-(3,5-dimethoxyphenylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(3-chlorphenylamino)-5-fluornicotinamid; 6-(2-aminoethylamino)-5-fluor-2-(quinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(isoquinolin-4-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(l,8-naphthyridin-3-ylamino)nicotinamid; 5- fluor-6-(2-(lH-imidazol-5-yl)ethylamino)-2-(quinolin-3-ylamino)nicotinamid; 6- ((lR)-2-amino-2-oxo-l-phenylethylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2R)-l-amino-4-methyl-l-oxopentan-2-ylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2R)-l-amino-l-oxobutan-2-ylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2S)-2-aminobutylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2S)-2-amino-3-methylbutylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2S)-2-amino-2-phenylethylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2R)-2-amino-3-methoxypropylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2S)-2-aminopropylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-((2S)-2-amino-4-methylpentylamino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-(3-aminopropylamino)-2-(3,5-dimethoxyphenylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluornicotinamid; 6-((lR,2S)-2-aminocyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluomicotinamid; 6-(cis-2-aminocyclohexylamino)-5-chlor-2-(quinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-bromo-2-(quinolin-3-ylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-chlor-2-(3-methoxyphenylamino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-chlor-2-(5-methylpyridin-3-ylamino)nicotinamid; og 6-(cis-2-aminocyclohexylamino)-5-bromo-2-(5-methylpyridin-3-ylamino)nicotinamid.
  27. 27. Forbindelse, der er valgt fra gruppen bestående af: 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(6-methylpyridin-3-ylamino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((5-cyano-6-morpholinopyridin-3-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-(5-methylpyridin-3-ylamino)nicotinamid; (R)-6-((l-amino-4-methylpentan-2-yl)amino)-5-fluor-2-((quinolin-6-yl)amino)nicotinamid; (R)-6-((l-amino-4-methylpentan-2-yl)amino)-5-fluor-2-((2-(2-methoxyethoxy)pyridin-4- yl)amino)nicotinamid; 6-((lR,2S)-2-aminocyclohexylamino)-5-fluor-2-((6-morpholinopyridin-3-yl)amino)nicotinamid; 2-((5-(lH-pyrazol-l-yl)pyridin-3-yl)amino)-6-((lR,2S)-2-aminocyclohexylamino)-5- fluornicotinamid; (R)-6-((l-amino-4-methylpentan-2-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5- fluornicotinamid; 6-(((2S,3R)-2-aminopentan-3-yl)amino)-2-((l-ethyl-lH-indazol-5-yl)amino)-5-fluornicotinamid; 6-(((2S,3R)-2-aminohexan-3-yl)amino)-5-fluor-2-((2-methoxypyridin-4-yl)amino)nicotinamid; 6-(((2S, 3R)-2-aminopentan-3-yl)amino)-5-fluor- 2-((5-(2- fluorphenyl)pyridin-3- yl)amino)nicotinamid; 6-(((2S,3R)-2-aminopentan-3-yl)amino)-5-fluor-2-((l-methoxyisoquinolin-6- yl)amino)nicotinamid; 6-(((2S,3R)-2-aminopentan-3-yl)amino)-5-fluor-2-((l-methyl-lH-indazol-4-yl)amino)nicotinamid; 6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluornicotinamid; 6-(((2S,3R)-2-aminohexan-3-yl)amino)-5-fluor-2-((5-fluorpyridin-3-yl)amino)nicotinamid; 6-(((2S,3R)-2-aminohexan-3-yl)amino)-5-fluor-2-((2-propoxypyridin-4-yl)amino)nicotinamid; (R)-6-((l-amino-4-methylpentan-2-yl)amino)-2-((l-ethyl-lH-indazol-5-yl)amino)-5- fluornicotinamid; 6-(((2R,3S)-3-amino-l-cyclopropylbutan-2-yl)amino)-2-((l-ethyl-lH-indazol-5-yl)amino)-5- fluornicotinamid; 6-((( IR,2S)-2-amino-l-cyclopropylpropyl)amino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-(((lR,2S)-2-aminocyclohexyl)amino)-5-fluor-2-((6-methyl-5-(2H-l,2,3-triazol-2-yl)pyridin-3- yl)amino)nicotinamid; 6-(((lR,2S)-2-aminocyclohexyl)amino)-5-fluor-2-((6-methoxy-5-(2H-l,2,3-triazol-2-yl)pyridin-3- yl)amino)nicotinamid; 6-(((2S,3R)-2-amino-5-methylhexan-3-yl)amino)-5-fluor-2-((l-methyl-lH-indazol-5- yl)amino)nicotinamid; 6-(((2S,3R)-2-amino-5-methylhexan-3-yl)amino)-2-((l-ethyl-lH-indazol-5-yl)amino)-5- fluornicotinamid; 6-((( IR,2S)-2-aminocyclohexyl)amino)-5-fluor-2-((5-fluor-6-morpholinopyridin-3-yl) amino)nicotinamid; 6-((( IR,2S)-2-aminocyclohexyl)amino)-2-((2-ethoxy-3-fluorpyridin-4-yl)amino)-5-fluornicotinamid; 6-(((2R,3S)-3-amino-l-cyclopropylbutan-2-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5- fluornicotinamid; 6-(((2S,3S)-3-amino-l-methoxybutan-2-yl)amino)-5-fluor-2-(quinolin-6-ylamino)nicotinamid; 6-(2-aminoethylamino)-2-(3,5-dimethoxyphenylamino)-5-fluornicotinamid; 6-(((IR,2S)-2-aminocyclohexyl)amino)-5-fluor-2-((5-methylpyridin-3-yl)amino)-nicotinamid og 6(((lR,2S)-2-aminocyclohexyl)amino)-5-fluor-2-((6-methylpyridin-3-yl)amino)-nicotinamid.
  28. 28. Forbindelse, der er valgt fra gruppen bestående af: 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((6-methyl-5-phenylpyridin-3-yl)amino)-nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluornicotin-amid; 2-(lH-indazol-4-yl)amino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((l-(2-(pyrrolidin-l-yl)ethyl)-lH-indazol-4- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((l-(2-morpholinoethyl)-lH-indazol-4-yl)- amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((l-(cyclopropylmethyl)-lH-indazol-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((l-(2-methoxyethyl)-lH-indazol-4- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((l-(2-(2-ethoxyethoxy)ethyl)-lH-indazol-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(cyclopropylmethyl)-2H-indazol-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-benzyl-2H-indazol-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-methoxyethyl)-2H-indazol-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-benzyl-2H-indazol-5-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((5-ethylpyridin-3-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-methyl-2H-indazol-5-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((l-(cyclopropylmethyl)-lH-indazol-6-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((l-(2-methoxyethyl)-lH-indazol-6-yl) amino)nicotinamid; 2-(2-( lH-pyrrol-2-yl)pyridin-4-yl)amino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-phenylpyridin-4-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(furan-2-yl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-isopropoxypyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(furan-3-yl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(methylamino)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(2-ethoxypyridin-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-(2,6-diethoxypyridin-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((5-(5-methylfuran-2-yl)pyridin-3-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-((5-methylfuran-2-yl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-methoxy-6-phenylpyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-methoxyethoxy)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-morpholino-6-phenylpyridin-4-yl) amino)nicotinamid; 2-((5-(lH-pyrazol-4-yl)pyridin-3-yl)amino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotinamid; 2-(2-( lH-pyrazol-4-yl)pyridin-4-yl)amino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotin amid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-propoxypyridin-4-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-butoxypyridin-4-yl)amino)-5-fluomicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-isobutoxypyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-methoxyquinolin-7-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-methoxyethoxy)quinolin-7-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-((l-methoxypropan-2-yl)oxy)quinolin-7- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(3-methoxybutoxy)quinolin-7-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2-ethoxyethoxy)ethoxy)quinolin-7-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((5-(l-cyclohexen-l-yl)pyridin-3-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-methoxyethoxy)quinolin-6-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-((l-methoxypropan-2-yl)oxy)quinolin-6- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(3-methoxybutoxy)quinolin-6-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2-ethoxyethoxy)ethoxy)quinolin-6-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-methoxyquinolin-6-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-ethoxyquinolin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-propoxyquinolin-6-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2-ethoxyethoxy)quinolin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-(2-methoxyethoxy)ethoxy)quinolin-6- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-((tetrahydrofuran-2-yl)methoxy)quinolin-6- yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-(2-oxopyTrolidin-l-yl)ethoxy)quinolin-6- yl)amino)nicotinamid; 2-((2-(lH-l,2,4-triazol-l-yl)pyridm-4-yl)amino)-6-(cis-2-aminocyclohexy)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((5-(furan-3-yl)-6-methylpyridin-3-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2,3-dimethoxyquinoxalin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2,3-diethoxyquinoxalin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((4-methyl-3,4-dihydro-2H-[l,4]oxazino[2,3- b]quinoxalin-7-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2,3-diniethylquinoxalin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2,3-diethylquinoxalin-6-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((l-ethyl-lH-indazol-5-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((l-propyl-lH-indazol-5-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-fluoiphenyl)pyTidin-4-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2,4-difluorphenyl)pyTidin-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((6-methyl-5-(2H-l,2,3-triazol-2-yl)pyridin-3- yl)amino)nicotinamid; 2-((5-(lH-l,2,4-triazol-l-yl)pyridm-3-yl)amino)-6-(cis-2-aminocyclohexylamino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-fluor-3-methoxyphenyl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-fluor-4-methoxyphenyl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(2-fluor-5-methoxyphenyl)pyridin-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((6-cyclopropylpyridin-3-yl)amino)-5-fluornicotinamid; 2-((3-(lH-pyrazol-l-yl)quinolin-7-yl)amino)-6-(cis-2-aminocyclohexylamino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2,3-difluorphenyl)pyridin-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(2,5-difluorphenyl)pyridin-4-yl)amino)-5-fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-(3-chlor-2-fluorphenyl)pyridin-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((2-((5-chlor-2-fluorphenyl)pyridin-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-2-((5-(benzo[d][l,3]dioxol-5-yl)pyridin-3-yl)amino)-5- fluornicotinamid; 6-(cis-2-ammocyclohexylamino)-2-((2-(benzo[d][l,3]dioxol-5-yl)pyridin-4-yl)amino)-5- fluornicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((5-(3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-6- yl)pyridin-3-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-6- yl)pyridin-4-yl)amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(3-methoxyphenyl)pyridm-4-yl) amino)nicotinamid; 6-(cis-2-aminocyclohexylamino)-5-fluor-2-((2-(4-methoxyphenyl)pyridm-4-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-ethyl-lH-indazol-6-yl)amino)-5-fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-ethyl-lH-indazol-4-yl)amino)-5-fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-(2,2-difluorethyl)-lH-indazol-5-yl)amino)-5- fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-(2,2-difluorethyl)-lH-indazol-6-yl)amino)-5- fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((5-(quinolin-7-yl)pyridin-3-yl)amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((5-(isoquinolin-6-yl)pyridin-3-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((5-(isoquinolin-7-yl)pyridin-3-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((2-(quinolin-7-yl)pyridin-4-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((2-(isoquinolin-6-yl)pyridin-4-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((2-(isoquinolin-7-yl)pyridin-4-yl) amino)nicotinamid; 6-(((cis)-2-aminocyclohexyl)amino)-2-((benzofuro[2,3-b]pyridin-3-yl)amino)-5-fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((3-fluor-l-methyl-lH-indazol-5-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-ethyl-3-fluor-lH-indazol-5-yl)amino)-5-fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((3-fluor-l-methyl-lH-indazol-6-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-ethyl-3-fluor-lH-indazol-6-yl)amino)-5-fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((l-(2-fluorethyl)-lH-indazol-5-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-(( 1-(2- fluorethyl)-lH-indazol-6-yl) amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((3-fluor-l-(2-fluorethyl)-lH-indazol-5- yl)amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((3-fluor-l-(2-fluorethyl)-lH-indazol-6- yl)amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l,3-dimethyl-lH-indazol-5-yl)amino)-5-fluomicotinamid; 6-((cis-2-aminocyclohexyl)amino)-2-((l-ethyl-3-methyl-lH-indazol-5-yl)amino)-5- fluornicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((l-(2-methoxyethyl)-3-methyl-lH-indazol-5- yl)amino)nicotinamid; 6-((cis-2-aminocyclohexyl)amino)-5-fluor-2-((l-(2-fluorethyl)-3-methyl-lH-indazol-5-yl)amino)nicotinamid og 6-((cis-2-aminocyclohexyl)amino)-2-((l-(2,2-difluorethyl)-3-methyl-lH-indazol-5-yl)amino)-5- fluornicotinamid.
DK11801034.7T 2010-06-30 2011-06-30 Hidtil ukendte nicotinamidderivater eller salte deraf DK2589592T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010150495 2010-06-30
PCT/JP2011/065530 WO2012002577A1 (ja) 2010-06-30 2011-06-30 新規なニコチンアミド誘導体またはその塩

Publications (1)

Publication Number Publication Date
DK2589592T3 true DK2589592T3 (da) 2018-11-26

Family

ID=45402271

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11801034.7T DK2589592T3 (da) 2010-06-30 2011-06-30 Hidtil ukendte nicotinamidderivater eller salte deraf

Country Status (21)

Country Link
US (1) US8895585B2 (da)
EP (1) EP2589592B1 (da)
JP (1) JP5744021B2 (da)
KR (1) KR101789129B1 (da)
CN (1) CN102958918B (da)
AU (1) AU2011272198B2 (da)
BR (1) BR112012033770A2 (da)
CA (1) CA2803842C (da)
DK (1) DK2589592T3 (da)
ES (1) ES2689103T3 (da)
HK (1) HK1181762A1 (da)
IL (1) IL223818B (da)
MX (1) MX2012015023A (da)
MY (1) MY177250A (da)
NZ (1) NZ603837A (da)
PL (1) PL2589592T3 (da)
RU (1) RU2560163C2 (da)
SG (1) SG186877A1 (da)
TW (1) TWI561512B (da)
WO (1) WO2012002577A1 (da)
ZA (1) ZA201300095B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635556B1 (en) 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
WO2012162291A1 (en) * 2011-05-24 2012-11-29 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
ES2661444T3 (es) 2011-12-28 2018-04-02 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
CA2886117C (en) * 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
ES2813875T3 (es) * 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
JP6472419B2 (ja) 2015-09-30 2019-02-20 富士フイルム株式会社 芳香族化合物の製造方法
KR20180072704A (ko) 2015-10-23 2018-06-29 나비토르 파마슈티칼스 인코포레이티드 세스트린-gator2 상호작용의 조절제 및 이의 용도
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
KR102524773B1 (ko) 2017-01-26 2023-04-21 싸이클라셀 리미티드 퓨린 유도체의 제조 방법
MD3448859T2 (ro) 2017-03-20 2020-03-31 Forma Therapeutics Inc Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
CA3061611A1 (en) 2017-04-26 2018-11-01 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
AU2018269947B2 (en) * 2017-05-15 2021-10-14 The Regents Of The University Of Michigan Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
AU2018286247B2 (en) * 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
DK3724190T3 (da) 2017-12-13 2022-10-10 Lupin Ltd Substituerede bicykliske heterocykliske forbindelser som PRMT5 inhibitorer
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
JP2022505849A (ja) 2018-10-24 2022-01-14 ナビター ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
WO2020128020A2 (de) * 2018-12-21 2020-06-25 Saltigo Gmbh Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3980417B1 (en) 2019-06-10 2023-09-27 Lupin Limited Prmt5 inhibitors
CN112538072B (zh) * 2019-09-21 2024-02-06 齐鲁制药有限公司 氨基嘧啶类egfr抑制剂
MX2022005215A (es) 2019-11-01 2022-06-08 Navitor Pharm Inc Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR121149A1 (es) 2020-01-30 2022-04-20 Fmc Corp Compuestos piridina para controlar plagas de invertebrados
TW202317528A (zh) 2021-06-24 2023-05-01 美商富曼西公司 用於防治無脊椎有害生物的唑類化合物
CN114230490A (zh) * 2021-12-28 2022-03-25 乐威医药（江苏）股份有限公司 一种n-烷基化双胺的制备方法
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133253A (en) 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
WO2002012238A2 (en) 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES
MXPA03007765A (es) 2001-03-01 2003-12-08 Shionogi & Co Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa.
CN1589277A (zh) 2001-09-17 2005-03-02 奥索-麦克尼尔药品公司 6－o－氨基甲酸酯－11,12－内酯－酮内酯抗菌剂
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US20060079522A1 (en) 2004-10-08 2006-04-13 Marzabadi Mohammad R Amino substituted aryloxybenzylpiperidine derivatives
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
PT1846394E (pt) * 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
RU2415852C2 (ru) * 2005-02-04 2011-04-10 Астразенека Аб Производные пиразолиламинопиридина, пригодные в качестве ингибиторов киназы
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
KR101411695B1 (ko) * 2006-02-17 2014-07-03 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CN101466676B (zh) 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
EP2069851A4 (en) 2006-09-14 2010-02-24 Tessera Tech Hungary Kft IMAGING SYSTEM WITH ASSOUPLY ASSEMBLED TOLERANCES AND ASSOCIATED METHODS
EP2079738A2 (en) 2006-10-27 2009-07-22 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
CN101605761A (zh) 2007-02-23 2009-12-16 卫材R&D管理有限公司 对hgfr基因扩增细胞株显示优异的细胞增殖抑制效果和抗肿瘤效果的吡啶衍生物或嘧啶衍生物
TW200904421A (en) * 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
WO2009018344A1 (en) 2007-07-30 2009-02-05 Regents Of The University Of Minnesota Anticancer agents
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
AR068509A1 (es) * 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
CA2960692C (en) 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
JP2011524398A (ja) 2008-06-16 2011-09-01 エフ．ホフマン−ラ ロシュ アーゲー オレキシニン受容体アンタゴニストとしてのヘテロ芳香族モノアミド
CN102112942A (zh) * 2008-07-31 2011-06-29 圣纳普斯有限责任公司 基于计算机的算盘训练系统
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2635556B1 (en) * 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators

Also Published As

Publication number Publication date
RU2560163C2 (ru) 2015-08-20
SG186877A1 (en) 2013-02-28
NZ603837A (en) 2014-01-31
AU2011272198A1 (en) 2013-02-07
MX2012015023A (es) 2013-04-03
US8895585B2 (en) 2014-11-25
EP2589592B1 (en) 2018-08-22
ES2689103T3 (es) 2018-11-08
TWI561512B (en) 2016-12-11
WO2012002577A1 (ja) 2012-01-05
HK1181762A1 (zh) 2013-11-15
BR112012033770A2 (pt) 2016-11-22
AU2011272198B2 (en) 2016-09-22
CN102958918B (zh) 2015-12-09
MY177250A (en) 2020-09-10
CA2803842C (en) 2020-01-07
CN102958918A (zh) 2013-03-06
IL223818B (en) 2019-09-26
KR101789129B1 (ko) 2017-11-20
JPWO2012002577A1 (ja) 2013-08-29
KR20130088130A (ko) 2013-08-07
TW201215602A (en) 2012-04-16
CA2803842A1 (en) 2012-01-05
EP2589592A1 (en) 2013-05-08
RU2013103792A (ru) 2014-08-10
JP5744021B2 (ja) 2015-07-01
US20130116430A1 (en) 2013-05-09
EP2589592A4 (en) 2014-01-01
ZA201300095B (en) 2014-03-26
PL2589592T3 (pl) 2019-03-29

Similar Documents

Publication Publication Date Title
DK2589592T3 (da) Hidtil ukendte nicotinamidderivater eller salte deraf
ES2586856T3 (es) Compuestos heterocíclicos útiles como inhibidores de PDK1
JP5989805B2 (ja) メチル基変更酵素の調節物質、組成物及びその使用
WO2016011390A1 (en) Irak4 inhibiting agents
WO2015074081A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
EP2723717A2 (en) Trpm8 antagonists and their use in treatments
TWI822754B (zh) 作為crhr2拮抗劑之稠合環狀脲衍生物
JP7282743B2 (ja) 複素環化合物
AU2018244211A1 (en) Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
TWI834641B (zh) 血漿激肽釋放素抑制劑及其用途
JP2023544789A (ja) Ｍｒｇｘ２アンタゴニスト